mAbs

Views & Analysis

Artificial Intelligence for better antibody drugs: ready for...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.

Views & Analysis

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

How cell and gene therapies are transforming pharma deal-mak...

After decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to deliver with the first generation of promising new cel

News

Dr Maky Zanganeh, Summit's president and chief executive

FDA won't approve Summit, Akeso's ivonescimab

The FDA has said it cannot approve Summit /Akeso's ivonescimab, delaying a drug that could usher in a new era of dual-acting cancer immunotherapies.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Editor's Picks